RE:Spanish Researchers inspired by success of TLD1433 Thanks Eoganacht....another great find.
Our trial could be "the trial" that sets a new clinical precedent for non platinum-based metal drugs in the treatment of cancer. There's too much good research supporting their clinical application....And the versatility of Ruthenium gives it a distinct edge over platinum drugs.
It was Dr. McFarland's lab that had recently discovered a new Ruthenium compound (referred to as an "Ubertoxin") that demonstrated inexplicable potency in extreme hypoxia. Its anticancer effect against cancer cells were reported to be the "largest to date for any compound class". Additionally, preclinical studies using a Ruthenium complex in combination with chemotherapy (Doxorubicin) had demonstrated significant anticancer/synergistic potential in a breast cancer cell line...that was w/o the help of light/PDT.
Per Reasearch Capital....(Biotuesdays: April 27, 2023)
"We believe Ruvidar has the potential to achieve a better and longer duration of complete response (CR) than Merck’s Keytruda”
"We believe the data is solid for treating NMIBC and we believe the company needs to hire a strong regulatory FDA consultant to help them start preparing their NDA package as clinical data continues to come in”
"We believe the pivotal trial with Ruvidar in BCG-unresponsive NMIBC continues moving in the right direction. More interim data of the pivotal trial should be disclosed in 2023”
With a name like Ruvidar, how can it not become a commercial success. JMHO.